Epidemiology and Survival outcomes of HIV-associated cervical cancer in Nigeria
Author:
Musa JonahORCID, Kocherginsky Masha, Magaji Francis A., Maryam Ali J., Asufi Joyce, Nenrot Danjuma, Burdett Kristen, Katam Neelima, Christian Elizabeth N., Palanisamy Nisha, Odukoya Olukemi, Silas Olugbenga A., Abdulkareem Fatimah, Akpa PhilipORCID, Badmos Kabir, Imade Godwin E., Akanmu Alani S., Gursel Demirkan B., Zheng Yinan, Joyce Brian T.ORCID, Achenbach Chad J., Sagay Atiene S., Anorlu Rose, Wei Jian-Jun, Ogunsola Folasade, Murphy Robert L., Hou Lifang, Simon Melissa A.
Abstract
AbstractIntroductionInvasive cervical cancer (ICC) is an HIV-associated cancer that is preventable and precancerous stages including early ICC stages could be detected through screening offering opportunities for treatment and cure. The high incidence in women living with HIV and late presentation often at advanced stages of ICC with limited treatment facilities often result in early mortality. We sought to compare the epidemiologic characteristics and survival differences in HIV status of ICC patients in Nigeria.MethodsWe conducted a cohort study at two federal academic hospital-based research sites in Jos University Teaching Hospital, and Lagos University Teaching Hospital Nigeria, between March 2018 and September 2022. We enrolled women with histologically confirmed ICC with known HIV status, and FIGO staging as part of the United States of America’s National Institutes of Health/National Cancer Institute funded project titled ‘Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria’. The primary outcome was all-cause mortality with assessment of overall survival (OS) and time to death after ICC diagnosis. OS distribution was estimated using the method of Kaplan-Meier and compared between groups using the log-rank test.ResultsA total of 239 women with confirmed ICC were enrolled and included in this analysis, of whom 192 (80.3%) were HIV-negative (HIV-/ICC+), and 47 (19.7%) were HIV-positive (HIV+/ICC+). The HIV+/ICC) patients were younger with median age 46 (IQR: 40-51) years compared to 57 (IQR: 45-66) among HIV-/ICC+) (P<0.001. Squamous cell carcinoma was the commonest histopathologic variant in 80.4% of ICC diagnosis, moderately differentiated tumor grade in 68.1% in both groups. HIV+/ICC+ diagnosis was at FIGO advanced stages in 64.9% compared to 47.9% in HIV-/ICC+. The HIV-/ICC+ women had better OS compared to HIV+/ICC+ participants (p=0.018), with 12-month OS 84.1% (95%CI: 75% - 90%) and 67.6% (95%CI: 42%-84%) respectively.ConclusionICC is diagnosed at a relatively young age in women living with HIV, with a significantly lower overall survival probability compared to women without HIV. The trend of presentation and diagnosis at advanced stages in women living with HIV could partly explain the differences in overall survival.
Publisher
Cold Spring Harbor Laboratory
Reference33 articles.
1. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative;Lancet Glob Health,2023 2. Arbyn M , Weiderpass E , Bruni L , de Sanjosé S , Saraiya M , Ferlay J , et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2019. 3. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study;Global Burden of Disease Cancer C;JAMA Oncol.,2017 4. Reflection: burden of cervical cancer in Sub-Saharan Africa and progress with HPV vaccination;Curr Opin Immunol,2021 5. Estimates of the global burden of cervical cancer associated with HIV;The Lancet Global Health,2021
|
|